Journal article

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade

T Gargett, W Yu, G Dotti, ES Yvon, SN Christo, JD Hayball, ID Lewis, MK Brenner, MP Brown

Molecular Therapy | CELL PRESS | Published : 2016

Abstract

Chimeric antigen receptor (CAR) T cells have shown great promise in the treatment of hematologic malignancies but more variable results in the treatment of solid tumors and the persistence and expansion of CAR T cells within patients has been identified as a key correlate of antitumor efficacy. Lack of immunological "space", functional exhaustion, and deletion have all been proposed as mechanisms that hamper CAR T-cell persistence. Here we describe the events following activation of third-generation CAR T cells specific for GD2. CAR T cells had highly potent immediate effector functions without evidence of functional exhaustion in vitro, although reduced cytokine production reversible by PD-..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Cancer Institute


Funding Acknowledgements

We acknowledge funding support from NHMRC Project Grant APP1010386 and the Therapeutic Innovation Australia Researcher Access Scheme. We thank Zhuyong Mei, Oumar Diouf, Adrian Gee, and Debbie Lyons from CAGT, Baylor College of Medicine for assistance with retroviral vector production and shipping and associated protocols. We also thank Cara Fraser for assistance with standard operating procedures, Smita Hiwase, Pam Dyson and Kerry Munro at the Therapeutic Products Facility, SA Pathology, and Andy Flies from the Experimental Therapeutics Laboratory, University of South Australia.